Transaction Reports TheraVectys TheraVectys

secures €7.48m from private investors

Legal advisor to TheraVectys:

Theravectys secures €7.48m from private investors

THERAVECTYS, a biotechnology company that is developing a new generation of vaccines based on lentiviral vector technology, announced that it has secured 7.48 million euros as of the end of H1 2012. These funds, raised exclusively from private investors, will enable THERAVECTYS to pursue the development of a new generation of vaccines, with an anti-HIV therapeutic vaccine as its first priority.

Financial advisor to the equity provider:

CAMDEN ASSOCIATES Tax advisor:

CABINET VIZZAVONA IP due diligence provider:

Law Office of Salvatore Arrigo and Scott Lee, LLP

For this third funding round, Guy Paillaud, former executive manager of Promodes, and John Pieters, former CEO of Amgen France - some of the company's historical investors - have been joined by 10 new private investors, which include the Tethys fund (Bettencourt family), Philippe Oddo and Richard Hennessy.

In particular, this new amount of funds raised will enable

the company to fund: • Phase I/II of the clinical trial of its anti-HIV vaccine candidate;

• The development of new vaccine candidates based on lentiviral vector technology and concerning other indications;

• The planning of new laboratories that are larger and can better accommodate the company's development.

"We thank our investors—both old and new—for the trust that they have placed in us. Thanks to their support, within the next two years we hope to be able to demonstrate in humans not only the safety but also the potential effectiveness of our anti-HIV vaccine candidate," says Renaud Vaillant, CEO at Theravectys who adds that "this funding should also allow us to continue and even strengthen our efforts in research and development of new indications alone or in collaboration with other large pharmaceutical laboratories."

"The anti-HIV therapeutic vaccine developed by Theravectys should enable HIV-positive patients under combination therapies, once vaccinated, to discontinue and perhaps even permanently stop taking any antiretroviral treatment," explains Jean-Pierre Meyers, CEO of Tethys, "Despite all of the progress made, funding for these antiretroviral treatments still remains a public health challenge, without taking into account the numerous secondary effects. Development of an anti-HIV vaccine would enable providing access to effective treatment to not only those who, within developing countries which lack the resources, do not yet have access to care; but this vaccine would also relieve our health care systems that are suffering due to the economic crisis.”

Guy Paillaud, historical shareholder in the company, adds: "Today I measure the progress made by the company: Theravectys would be the first company in the world to initiate a clinical trial of an anti-HIV therapeutic vaccine with lentiviral vectors. Despite the tough economic times, this fundraising is the fruit of the work performed by Renaud Vaillant and his team."

"All of the company's investors measure the potential of lentiviral vector technology and the quality of the technology platform developed by Theravectys," explains Jean-Pierre Kinet, CEO of the company ixlife, the first investor in Theravectys, "Today, lentiviral vectors are the most powerful vectors for gene transfer. These vectors can reprogram the dendritic cells and, thus, induce an intense and diversified immune response that may enable treating not only HIV but also many other diseases, particularly cancer.”

Timbmet Door Solutions Ltd Laidlaw Interiors Group acquires Timbmet

Door Solutions Ltd for £7.8m Tax advisor and financial due diligence provider:

Laidlaw Interiors Group acquires Timbmet Door Solutions Ltd for £7.8m

Laidlaw Interiors Group Ltd, backed by the leading private equity fund Rutland Partners, has completed the acquisition of Mansfield based door manufacturer Timbmet Door Solutions Ltd (TDSL).

Legal advisors to Laidlaw Interiors Group:

Following the conditional agreement made in July, the parties made a voluntary submission to the Office of Fair Trading (OFT) to ensure that there were no competition issues arising from the merger. The OFT has carried out a thorough review of the market and has concluded that the merger will not result in any lessening of competition in the market. Consequently the transaction has now been cleared and was completed on 17th September 2012.

Operational due diligence provider: Commercial due diligence provider:

TDSL is a major supplier of performance doorsets for the non-domestic internal timber door market. The company employs around 200 people in the UK with offices in Leicester, London, Manchester, Mansfield, Shrivenham and Stockton and operates a modern production facility in Mansfield. It also has a manufacturing facility in India supporting international building projects.

Laidlaw Interiors Group is the UK’s leading

supplier of integrated interior products. Its brands include office fit out and partitioning specialist Komfort, door manufacturer Leaderflush Shapland and ironmongery, doorsets, access control and balustrading supplier Laidlaw Solutions. The Group also incorporates Cubicle Systems washrooms and Tufwell Glass.

“TDSL brings to LIG an excellent product range, access to international markets and wider customer reach, backed by an exemplary approach to service. The combined businesses will greatly enhance the value we can provide to our customers through a more integrated and flexible supply chain. Throughout this process we have looked at all options to keep the Barnstaple manufacturing operation open as the commitment of the team there has been exceptional. Unfortunately, we have been unable to find a commercially viable solution and as such we expect manufacturing will cease at the end of November 2012. We have commenced consultation with the work force to ensure the impact of this decision will be minimised. We will however continue to have a commercial office in Barnstaple to support our wider business.” Laidlaw Interiors Group CEO, John Jefferies